Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» CAR-T
CAR-T
ASH17: Benefit of Gilead's CAR-T remains durable over longer term
BioPharma Dive
Sun, 12/10/17 - 11:27 pm
ASH17
Gilead Sciences
CAR-T
Yescarta
diffuse large B-cell lymphoma
#ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?
Endpoints
Sun, 12/10/17 - 11:10 am
ASH17
Novartis
Kymriah
DLBCL
CAR-T
diffuse large B-cell lymphoma
Juno uses lethal neurotox lessons to guide Goldilocks formula for its next-gen CAR-T
Endpoints
Mon, 11/13/17 - 09:18 am
Juno Therapeutics
CAR-T
JCAR017
Juno analysis of shuttered study offers clues for CAR-T
BioPharma Dive
Fri, 11/10/17 - 10:30 pm
Juno Therapeutics
CAR-T
JCAR015
clinical trials
9 Notable Biotechs Presenting At This Year's ASH Meeting
Yahoo
Tue, 11/7/17 - 09:56 am
ASH
Bluebird Bio
LentiGlobin
Ziopharm Oncology
Bellicum
BPX-501
Spark Therapeutics
SPK-8011
Biomarin
BMN 270
Juno Therapeutics
CAR-T
Novartis
Geron
imetelstat
Immunogen
IMGN632
IMGN779
FDA lifts hold on Cellectis’ CAR-T trial, adds go-slow caveat
Fierce Biotech
Tue, 11/7/17 - 09:38 am
FDA
Cellectis
CAR-T
clinical trials
UCART123
Novartis seeks European approval for cell therapy Kymriah
Reuters
Mon, 11/6/17 - 09:25 am
Novartis
Europe
CAR-T
Kymriah
diffuse large B-cell lymphoma
acute lymphoblastic leukemia
#ASH17: The big loser in CAR-T, Juno is making a bid to seize the fast lane to frontrunner status
Endpoints
Wed, 11/1/17 - 06:52 pm
ASH
CAR-T
Juno Therapeutics
JCAR017
Novartis hustles along another FDA application for CAR-T star, tackling Gilead head on
Endpoints
Tue, 10/31/17 - 09:38 am
Novartis
FDA
CAR-T
Kymriah
diffuse large B-cell lymphoma
Gilead Slaps Mega-Price on Its Newly Approved CAR-T
Motley Fool
Fri, 10/20/17 - 09:04 am
Gilead Sciences
CAR-T
drug pricing
Yescarta
Kite Pharma
Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nod
Fierce Pharma
Thu, 10/19/17 - 09:12 am
Gilead Sciences
Kite Pharma
Novartis
CAR-T
FDA
axi-cel
Yescarta
non-Hodgkin's lymphoma
large B-cell lymphoma
4 Ways To Market CAR-T Therapies
Medical Marketing and Media
Mon, 10/16/17 - 09:43 pm
drug marketing
CAR-T
5 Game-Changing Cancer Drug Innovations Being Developed Right Now
Motley Fool
Thu, 10/12/17 - 10:45 am
cancer
cancer immunotherapies
CAR-T
T-cell receptors
TCR therapeutics
IDO inhibitors
epigenetics
As CAR-T launch ramps up in U.S., Novartis' Narasimhan looks to convince Japan on performance-based pricing
Fierce Pharma
Thu, 10/5/17 - 06:16 pm
Novartis
CAR-T
Vas Narasimhan
Japan
drug pricing
performance-based pricing
Next-gen CAR-T, TCR player Autolus gains $80M for clinical trial work
Endpoints
Tue, 09/26/17 - 11:32 am
CAR-T
TCR-targeted drugs
Autolus
clinical trials
Premium price for Novartis' CAR-T sparks pushback from top PBM
BioPharma Dive
Mon, 09/25/17 - 07:23 pm
Novartis
Kymriah
CAR-T
drug pricing
Express Scripts
PBMs
Express Scripts' Miller Backs New Pricing Models for CAR-T
BioCentury
Fri, 09/22/17 - 09:13 am
Express Scripts
drug pricing
CAR-T
gene therapy
Kymriah
New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths
Xtalks
Wed, 09/20/17 - 10:41 am
CAR-T
Juno Therapeutics
Kite Pharma
Cellectis
On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy
Xconomy
Tue, 09/19/17 - 08:43 am
CAR-T
Novartis
Seattle Children's
pediatric cancer
ALL
gene therapy
Cell therapy emergence opens up new markets for shippers, logistic companies
BioPharma Dive
Fri, 09/8/17 - 09:41 am
cell therapy
logistics
CAR-T
Cryoport
GE Healthcare
Pages
« first
‹ previous
…
14
15
16
17
18
19
20
21
22
…
next ›
last »